高血压的药物研发：我们是否需要另一种抗高血压药物来治疗顽固性高血压？
Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension?
作者信息
Pimenta Eduardo, Calhoun David A
机构信息
Experimental Medicine CV/Hem, Clinical Sciences, Drug Discovery, Bayer Pharma AG, Aprather Weg 18a, Building 429, 42113, Wuppertal, Germany.
Sleep/Wake Disorders Center, Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
出版信息
Curr Hypertens Rep. 2016 Apr;18(4):25. doi: 10.1007/s11906-016-0634-9.
The prevalence of resistant hypertension is seemingly much lower than had been reported in early studies. Recent analyses suggest that <5 % of treated hypertensive patients remain uncontrolled if fully adherent to an optimized antihypertensive treatment. However, these patients do have increased cardiovascular risk and need effective therapeutic approaches. Drug development is a high-risk, complex, lengthy, and very expensive process. In this article, we discuss the factors that should be considered in the process of developing a new agent for treatment of resistant hypertension.
顽固性高血压的患病率似乎远低于早期研究所报告的数值。近期分析表明，如果完全坚持优化的抗高血压治疗方案，接受治疗的高血压患者中不到5%的人血压仍未得到控制。然而，这些患者的心血管风险确实增加了，需要有效的治疗方法。药物研发是一个高风险、复杂、漫长且成本高昂的过程。在本文中，我们将讨论在研发治疗顽固性高血压新药的过程中应考虑的因素。
Zotero 插件